LYZZ Capital, founded in 2015, is a leading global healthcare-dedicated VC/PE firm based in Shanghai. They have a team of highly experienced investment and operating professionals with backgrounds in leading pharmaceutical/biotech companies and Wall Street firms. With over 15 years of biotech investment experience and a presence in China for over 10 years, LYZZ Capital invests in talents, assets, and technologies globally, with a focus on unmet medical needs and large market potential in China. Their portfolio includes companies like Qpex Biopharma, Alpha Biopharma, NewMed Medical, Neurelis, and Chipscreen. As of March 2020, they have made six investments, with their most recent investment being in Qpex Biopharma in October 2018.